Table 7.

Sensitivity analyses for the second-line injectable drugs

Culture, indirect testing	Culture, direct testing
Number of participants (studies)	Pooled sensitivity (95% CI)	Pooled specificity (95% CI)	Number of participants (studies)	Pooled sensitivity (95% CI)	Pooled specificity (95% CI)
All studies of second-line injectable drugs
1637 (14 studies)	76.9% (61.1 to 87.6)	99.5% (97.1 to 99.9)	947 (6 studies)	94.4% (25.2 to 99.9)	98.2% (88.9 to 99.7)
Consecutive or random sampling
1391 (9 studies)	76.5% (53.8 to 90.1)	99.7% (95.9 to 100.0)	419 (4 studies)	71.9% (9.6 to 98.4)	98.9% (87.4 to 99.9)
Cross-sectional studies
1035 (8 studies)	77.0% (51.5 to 91.3)	98.7% (94.7 to 99.7)	893 (5 studies)	99.2% (0.5 to 100.0)	99.1% (90.7 to 99.9)
Index test results blinded to reference standard results
1255 (8 studies)	74.3 (46.9 to 90.4)	98.9 (94.6 to 99.8)	809 (5 studies)	98.6% (12.7 to 100.0)	98.1% (81.7 to 99.8)
Reference standard results blinded to index test results
1102 (8 studies)	70.4% (42.7 to 88.4)	99.2% (94.7 to 99.9)	720 (3 studies)	99.0% (79.7 to 100.0)	98.9% (89.6 to 100.0)